Signal Advisors Wealth LLC Buys 3,166 Shares of Eli Lilly and Company $LLY

Key Points

• Signal Advisors Wealth LLC increased its stake in Eli Lilly and Company by 349.1%, acquiring an additional 3,166 shares to hold a total of 4,073 shares worth approximately $3.175 million.
• Eli Lilly recently reported quarterly earnings of $6.31 EPS, exceeding analysts' expectations of $5.59, with revenues reaching $15.56 billion, up 37.6% from the previous year.
• The company also announced a quarterly dividend of $1.50 per share, yielding 0.8%, and has set FY 2025 EPS guidance in the range of $21.750-23.000.

Signal Advisors Wealth LLC boosted its position in Eli Lilly and Company (NYSE:LLY - Free Report) by 349.1% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 4,073 shares of the company's stock after acquiring an additional 3,166 shares during the period. Signal Advisors Wealth LLC's holdings in Eli Lilly and Company were worth $3,175,000 at the end of the most recent quarter.

Several other hedge funds have also added to or reduced their stakes in the company. WestEnd Advisors LLC boosted its holdings in Eli Lilly and Company by 210.0% during the first quarter. WestEnd Advisors LLC now owns 31 shares of the company's stock worth $26,000 after buying an additional 21 shares during the last quarter. Wealth Preservation Advisors LLC bought a new position in Eli Lilly and Company during the first quarter worth about $27,000. Citizens National Bank Trust Department boosted its holdings in Eli Lilly and Company by 180.0% during the first quarter. Citizens National Bank Trust Department now owns 42 shares of the company's stock worth $35,000 after buying an additional 27 shares during the last quarter. Financial Gravity Asset Management Inc. bought a new position in Eli Lilly and Company during the first quarter worth about $40,000. Finally, Mascagni Wealth Management Inc. bought a new position in Eli Lilly and Company during the fourth quarter worth about $43,000. Institutional investors own 82.53% of the company's stock.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on the company. Wall Street Zen cut Eli Lilly and Company from a "strong-buy" rating to a "buy" rating in a report on Saturday. Leerink Partners restated a "market perform" rating and set a $715.00 target price on shares of Eli Lilly and Company in a report on Thursday, August 7th. UBS Group cut their price objective on Eli Lilly and Company from $1,050.00 to $895.00 and set a "buy" rating on the stock in a report on Friday, August 8th. Guggenheim cut their price objective on Eli Lilly and Company from $942.00 to $875.00 and set a "buy" rating on the stock in a report on Wednesday, August 13th. Finally, Daiwa America cut Eli Lilly and Company from a "strong-buy" rating to a "hold" rating in a report on Sunday, August 17th. One analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating and nine have given a Hold rating to the company's stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $939.61.

Eli Lilly and Company Price Performance

Shares of Eli Lilly and Company stock traded down $9.41 during trading on Friday, reaching $753.52. 7,319,147 shares of the company's stock were exchanged, compared to its average volume of 3,181,974. The company has a debt-to-equity ratio of 1.86, a quick ratio of 1.00 and a current ratio of 1.28. Eli Lilly and Company has a 1-year low of $623.78 and a 1-year high of $939.86. The company has a market cap of $713.17 billion, a P/E ratio of 49.25, a PEG ratio of 1.05 and a beta of 0.47. The firm's 50-day moving average price is $738.37 and its 200 day moving average price is $770.79.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last posted its quarterly earnings results on Thursday, August 7th. The company reported $6.31 EPS for the quarter, topping analysts' consensus estimates of $5.59 by $0.72. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The company had revenue of $15.56 billion during the quarter, compared to analysts' expectations of $14.40 billion. During the same quarter in the previous year, the firm earned $3.92 EPS. Eli Lilly and Company's revenue was up 37.6% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. As a group, research analysts anticipate that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Wednesday, September 10th. Stockholders of record on Friday, August 15th were paid a $1.50 dividend. The ex-dividend date of this dividend was Friday, August 15th. This represents a $6.00 annualized dividend and a dividend yield of 0.8%. Eli Lilly and Company's dividend payout ratio is presently 39.22%.

Insider Buying and Selling

In related news, CEO David A. Ricks purchased 1,632 shares of the firm's stock in a transaction dated Tuesday, August 12th. The stock was bought at an average price of $644.77 per share, with a total value of $1,052,264.64. Following the completion of the purchase, the chief executive officer owned 546,601 shares in the company, valued at approximately $352,431,926.77. This represents a 0.30% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Jamere Jackson bought 200 shares of the business's stock in a transaction that occurred on Friday, August 8th. The shares were acquired at an average price of $639.56 per share, for a total transaction of $127,912.00. Following the transaction, the director owned 9,402 shares in the company, valued at $6,013,143.12. This represents a 2.17% increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last quarter, insiders have acquired 4,514 shares of company stock valued at $2,894,841. Corporate insiders own 0.13% of the company's stock.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.